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Rheumatoid arthritis (RA) is an autoimmune disease that affects ∼1% of the world’s
population. B cells and autoantibodies play an important role in the pathogenesis of
RA. The P2RX7 receptor is an ATP-gated cation channel and its activation results
in the release of pro-inflammatory molecules. Thus, antagonists of P2RX7 have been
considered to have potential as novel anti-inflammatory therapies. Although originally
identified for its role in innate immunity, P2RX7 has recently been found to negatively
control Peyer’s patches (PP) T follicular helper cells (Tfh), which specialize in helping B
cells, under homeostatic conditions. We have previously demonstrated that PP Tfh cells
are required for the augmentation of autoimmune arthritis mediated by gut commensal
segmented filamentous bacteria (SFB). Thus, we hypothesized that P2RX7 is required
to control autoimmune disease by keeping the Tfh cell response in check. To test
our hypothesis, we analyzed the impact of P2RX7 deficiency in vivo using both the
original K/BxN autoimmune arthritis model and T cell transfers in the K/BxN system.
We also examined the impact of P2RX7 ablation on autoimmune development in
the presence of the gut microbiota SFB. Our data illustrate that contrary to exerting
an anti-inflammatory effect, P2RX7 deficiency actually enhances autoimmune arthritis.
Interestingly, SFB colonization can negate the difference in disease severity between
WT and P2RX7-deficient mice. We further demonstrated that P2RX7 ablation in the
absence of SFB caused reduced apoptotic Tfh cells and enhanced the Tfh response,
leading to an increase in autoantibody production. It has been shown that activation
of TIGIT, a well-known T cell exhaustion marker, up-regulates anti-apoptotic molecules
and promotes T cell survival. We demonstrated that the reduced apoptotic phenotype of
P2rx7−/− Tfh cells is associated with their increased expression of TIGIT. This suggested
that while P2RX7 was regulating the Tfh population by promoting cell death, TIGIT may
have been opposing P2RX7 by inhibiting cell death. Together, these results demonstrated
that systemic administration of general P2RX7 antagonists may have detrimental effects
in autoimmune therapies, especially in Tfh cell-dependent autoimmune diseases, and
cell-specific targeting of P2RX7 should be considered in order to achieve efficacy for
P2RX7-related therapy.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease that causes
chronic inflammation of the joints and affects∼1% of the world’s
population. Genetics play an important role in RA and the
disease concordance rate between monozygotic twins with RA is
∼15%, (1, 2). This suggests that other factors are also critically
involved in RA pathogenesis, including smoking, gender, and
a more recently discovered factor, the composition of the gut
microbiota (3–6). Autoantibodies (auto-Abs) play critical roles
in the pathogenesis of RA as they contribute to immune complex
formation and complement activation, leading to tissue damage
in the joints (7–12). T follicular helper (Tfh) cells are a subset of
CD4+ T cells that co-expresses high levels of the inhibitory co-
receptor PD-1 and the chemokine receptor CXCR5 (13–15). The
function of Tfh cells is to help germinal center B cells produce
high-titer, high-affinity, isotype-switched antibodies (Abs) and
differentiate into long-lived plasma cells. Therefore, an excessive
Tfh cell response can lead to over-productive auto-Ab responses
and autoimmune conditions including RA (16).
High concentrations of extracellular ATP, such as those
released by dying cells, can act as a danger signal by binding
to the P2RX7 purinergic receptor, an ATP-gated cation channel
(17). This activates the NLRP3 inflammasome pathway, which
ultimately leads to the maturation and release of the pro-
inflammatory cytokines IL-1β and IL-18 (18). Therefore, P2RX7
has been targeted as a means of developing anti-inflammatory
therapies in many autoimmune diseases (19). However, studies
examining the function of P2RX7 in autoimmunity using
P2RX7 deficient mouse models suggest a complicated role for
P2RX7, as P2RX7 deficiency can either suppress or exaggerate
disease phenotypes (20–22). In the context of rheumatoid
arthritis, there have been several clinical trials using P2RX7
antagonists as a means of reducing inflammation (19, 23,
24). However, while early results appeared to support the
beneficial effects of such treatment, P2RX7 antagonists failed
to improve arthritic symptoms in two recent RA clinical trials
(23, 24). Understanding the mechanisms by which P2RX7
impacts autoimmunity will provide the knowledge required to
properly target P2RX7 for therapeutic purposes. This is an urgent
task, since despite some initial setbacks, enthusiasm for P2RX7
antagonist therapy remains strong, as evidenced by the numerous
ongoing clinical trials with new P2RX7 agonist and antagonist
compounds (17, 19, 25).
Interestingly, although originally identified for its crucial role
in the innate immune response (19), P2RX7 has recently been
found to also play key roles in regulating T cell populations.
A pioneer report has shown that P2RX7 activation negatively
controls Tfh cell numbers in Peyer’s Patches (PPs), a type
of gut-associated lymphoid tissue, to promote host-microbiota
mutualism under homeostatic conditions (26). Additionally,
P2RX7 drives Th1 cell differentiation and controls the follicular
helper T cell population to protect against Plasmodium chabaudi
malaria (27). However, the role of P2RX7 in the Tfh cell response
under autoimmune conditions is not known. Importantly, with
regard to inflammatory arthritis, a study found that 2 of 9 patients
with systemic juvenile idiopathic arthritis had loss-of-function
variants in P2rx7 (28). Therefore, we hypothesized that P2RX7
deficiency enhances autoimmune disease by increasing the Tfh
cell response. We have previously demonstrated that the gut
microbiota constituent segmented filamentous bacteria (SFB)
promote autoimmune arthritis via inducing PP Tfh cells (29).
Therefore, we also examined the impact of P2RX7 ablation on
autoimmune development in the presence of gut microbiota SFB.
Here, we use the K/BxN [KRN T cell receptor (TCR)
transgenic mice on the C57/BL6 (B6) background x NOD]
model to test our hypothesis. The K/BxN model is a murine
autoimmune arthritis model in which KRN T cells recognize
glucose-6-phosphate isomerase (GPI), the self-antigen presented
by MHC class II I-Ag7 from NOD mice (30). These activated
T cells can in turn activate B cells to produce anti-GPI
auto-Abs. K/BxN mice share many clinical and histologic
features with human RA patients (31). As in many human
autoimmune diseases including RA, auto-Abs play important
pathological roles in K/BxN disease development (31). An
advantage of the K/BxN model is that it has an easily
distinguishable initial T-B cell interaction phase and a later
effector phase involving innate immune players that allows
for a straightforward analysis of the immune response (32–
34). Thus, the intrinsic role of T cells can be easily dissected
out by using the K/BxN T cell transfer model. This is done
by transferring K/BxN T cells into T cell-deficient mice that
express MHC II I-Ag7 (30, 35). This approach allows for the
examination of T cell-specific P2RX7 contributions and avoids
many confounding effects from genetic modification of whole
animals. Here we demonstrated that P2RX7 deficiency in the
whole mouse caused augmented autoimmune arthritis, but SFB
colonization does not further exacerbate disease in P2RX7-
deficient K/BxN mice, as it does in wild type (WT) K/BxN
mice. Interestingly, the arthritis enhancement in SFB(–) mice
was reproducible simply by deleting P2RX7 in T cells, which
led to an enhanced Tfh cell response. Thus, unlike the anti-
inflammatory effect of P2RX7 blockade in innate immunity
reported previously, our results indicated that P2RX7 deletion
in T cells actually enhances autoimmunity by unleashing the Tfh
cell response.
MATERIALS AND METHODS
Mice
KRN TCR transgenic mice in the C57BL/6 (B6) background
(KRN), TCRα−/−.B6, and TCRα−/−.NOD mice were originally
obtained from the mouse colony of Drs. Diane Mathis and
Christophe Benoist at the Jackson Laboratory (Jax). K/BxN
mice were generated by crossing KRN mice to NOD mice
(All K/BxN experimental mice are the F1 offspring of KRN
and NOD parents). P2rx7−/−.B6 and P2rx7−/−.NOD mice
were purchased from Jax. P2rx7−/−.B6 were crossed to
KRN mice to generate P2rx7−/−.KRN mice. P2rx7−/−.K/BxN
mice were generated by crossing P2rx7−/−.KRN (in B6
background) to P2rx7−/−.NOD mice. TCRα−/−.BxN mice were
generated by crossing TCRα−/−.B6 with TCRα−/−.NOD mice.
TCRα−/−.BxN mice thus bear the NOD MHC class II, I-
Ag7, for self-Ag presentation. Age- and gender-matched K/BxN
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mice between 5 and 7 weeks old were used in experiments.
The K/BxN autoimmune model is a T cell receptor transgenic
model, therefore, its disease development is robust and occurs
in 100% of the F1 (KRNxNOD) offspring, regardless of
gender (32). Additionally, we compared arthritis development
between male and female K/BxN mice and found no significant
difference in disease severity (Supplementary Figure 1). For
transfer experiments, mice were given transfer cells at 6 weeks
old, and analysis was performed 2 weeks after transfer. Ankle
thickness was measured with a caliper (J15 Blet micrometer)
as described previously (36). All mice were housed at the SPF
animal facility at the University of Arizona. All experiments were
conducted in accordance with the guidelines of the University of
Arizona Institutional Animal Care and Use Committee Protocol
number 11-278.
Antibodies and Flow Cytometry
For surface staining, fluorophore-conjugated mAbs specific for
CD4 (RM4-5), CD19 (6D5), CD25 (PC61), CD11c (N418),
CD11b (M1/70), Gr-1 (RB6-8C5), CD45 (30-F11), TCRβ (H57-
597), PD-1 (RMP1-30), CD8α (53-6.7), CD3 (17A2), and
TIGIT (1G9) were obtained from BioLegend. Abs recognizing
CXCR5 (2G8) were from BD Pharmingen. Abs recognizing
P2RX7 (Hano43) were from Novus Biologicals. For intranuclear
staining, buffers from a Foxp3 Staining Buffer Set (eBioscience)
were used to stain with Abs recognizing Bcl-6(K112-91,
BD Pharmingen) and Foxp3 (FJK-16s, eBioscience). For
the cell death assay, cells were stained with Live/Dead R©
Yellow Dye (LifeTechnologies) and then surface markers,
and Annexin V binding accomplished using the Annexin
V/Dead Cell Apoptosis Kit (LifeTechnologies) according to
the manufacturer’s instructions. Cells were run on an LSRII
(BD Biosciences), and analyses were performed with FlowJo
(TreeStar) software.
ELISA
Anti-GPI Ab titers were measured as described (36). Briefly,
ELISA plates were coated with recombinant mouse GPI at
5µg/ml, and diluted mouse sera were added. Subsequently,
plates were washed and alkaline-phosphatase (AP)-conjugated
anti-mouse IgG Abs (Jackson ImmunoResearch) were added.
After the final wash, AP substrate was added and titers were
quantified as optical density values via an ELISA reader. Ab titers
were expressed as arbitrary units, which were calculated from
serial dilutions of sample serum and defined as the reciprocal of
the highest dilution that gave an above background O.D. value
set as 0.15.
Cell Transfer and Serum Transfer
T cells were transferred as described previously (35). Briefly,
splenic CD4+ T cells (5x105) were enriched by CD4-conjugated
MACS beads from K/BxN or P2rx7−/−.K/BxN mice and
adoptively transferred by retro-orbital (r.o.) injection into 6 week
old SFB(–) or SFB(+) Tcra−/−.BxN recipients. SFB status was
manipulated by gavaging recipient mice with SFB prior to cell
transfer. At the indicated time point after transfer, tissues from
recipient mice were harvested for flow cytometry analysis and
sera were collected for ELISA.
Microbiota Reconstitution and
Quantification
Our SPF mouse colony was derived as previously described (29).
SFB(–) Tcra−/−.BxNmice were weaned at 21 days old and rested
for 1 day. Then, mice were orally gavaged for 3 consecutive
days starting at 22 days old. SFB(–) mice were the ungavaged
littermate controls. The SFB colonization status was examined 10
days after the first gavage by SFB-specific 16S rRNA quantitative
PCR (36). To determine the change in SFB induced by transfer
of P2rx7−/−.K/BxN T cells, fecal samples were also collected at
the time of analysis, 2 weeks after the T cell transfer, and SFB
colonization was examined by quantitative PCR.
Statistical Analysis
Asterisks indicate statistical significance. Differences were
considered significant when P < 0.05 by Student’s t-test (two-
tailed, unpaired, with Welch’s correction) or one-way analysis of
variance (ANOVA) followed by Tukey’s multiple comparisons.
To compare ankle thickening, the area under the curve (AUC)
was calculated for each mouse within an experimental set
followed by a Student’s t-test between the groups (Prism 6,
Graph-Pad Software). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001,
∗∗∗∗P < 0.0001.
RESULTS
P2RX7 Deficiency Enhances Autoimmune
Arthritis Development
We first determined the role of P2RX7 in the spontaneous
K/BxN autoimmune arthritis model. Genetic P2RX7 deletion
(P2rx7−/− mice) in other autoimmune models has generated
results ranging from suppression, to no change, to exacerbation
of the autoimmune response compared to WT controls (20–
22). It is worth mentioning that some of these studies were not
using fully backcrossed mice and alternative P2RX7 functions
due to allelic differences among common inbred strains have
been reported (37–40). Due to the complexity of P2RX7, the
WT K/BxN and P2rx7−/−.K/BxN used in this study were in
a fixed B6xNOD background. We found enhanced arthritis
development in P2rx7−/− compared to WT K/BxN mice at an
early age, 4–6 weeks old (Figure 1A). In the K/BxN autoimmune
arthritis model, disease development is driven largely by anti-
GPI auto-Abs (30). Therefore, we examined the anti-GPI auto-
Ab titer in P2rx7−/− compared to WT K/BxN mice. The
increased susceptibility to disease development in P2rx7−/−mice
corresponded with an increased auto-Ab response (Figure 1B).
In the K/BxN model, therefore, complete P2RX7 deficiency
promoted an enhanced auto-Ab response, provoking early
disease onset compared toWT controls. There was no significant
change in T cell development in the thymus and we also did not
find any difference in peripheral immune populations including
CD4+ T cells and CD19+ B cells in spleen and PPs between
K/BxN and P2rx7−/−.K/BxN mice (Table 1). Furthermore,
no difference was found in the innate populations including
Gr-1+CD11b+ neutrophils and CD11c+ or CD11b+ antigen
presenting cells in spleen between K/BxN and P2rx7−/−.K/BxN
mice (Table 1).
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FIGURE 1 | P2RX7 deficiency leads to enhanced disease development in the
SFB(–) K/BxN model. (A) Ankle thickness was followed over time for K/BxN
and P2rx7−/−.K/BxN mice between ∼3.5 and 6 weeks of age. Data are
shown as change in ankle thickness compared to first measurement.
N = 9–14/group, 6 assays combined. (B) Anti-GPI auto-Ab titers in serum
obtained from the end point of each experiment were measured by ELISA.
N = 4–8/group, 6 assays combined. Error bars represent SEM. *p < 0.05.
Differing Impacts of P2RX7 Deficiency on
Systemic and PP Tfh Responses
Next, we aimed to determine the cellular mechanism that
caused the increased arthritis in P2rx7−/−.K/BxN mice. P2RX7
deficiency has been shown to increase PP Tfh cells in C57BL/6
(B6) mice, leading to an increase in IgA production in the PPs
(26). PP Tfh cells also play an important pathological role in the
development of arthritis in the K/BxN model, and an increase in
PP Tfh cells can lead to Tfh migration to systemic sites, driving
auto-Ab production (29). Because of this, we examined whether
P2RX7 deficiency causes an enhancement of the Tfh response
in both the gut and systemic sites, leading to exacerbation of
disease and auto-Ab production in the K/BxN model. As defined
in previous publications, we identified Tfh cells by high PD-
1 and CXCR5 expression in CD4+ T cells (29, 41–45). We
observed strong PP Tfh induction in P2rx7−/−.K/BxN mice,
analogous to what has been shown in P2RX7-deficient C57/BL6
mice [Figure 2A; (26)], however, there was no difference in
the number of Tfh cells in the spleen between P2rx7−/−
and WT K/BxN mice (Figure 2A). Because one of the major
consequences of P2RX7 activation is triggering cell death, and
P2RX7 controls the PP Tfh population by inducing cell death
(26), we examined whether differing levels of cell death in
P2RX7-deficient splenic and PP Tfh cells explain the different
responses to P2RX7 deletion in these tissues. Consistent with
previous reports, P2rx7−/−.K/BxN PP Tfh cells had a significant
reduction in cell death, as shown by decreased Annexin V
staining (among intact cells that excluded Live/Dead Yellow,
a membrane-impermeable dye) compared to WT K/BxN Tfh
cells (Figure 2B). This method of measuring cell death has been
shown to reliably distinguish early apoptotic cells from cells in
late-stage cell death (46). However, the difference in percentage
of apoptotic splenic Tfh cells between WT and P2RX7 deficient
mice is less compared to that of PP Tfh cells (Figure 2B); i.e.,
the average ratio of WT to P2rx7−/−.K/BxN apoptotic Tfh cell
TABLE 1 | Comparison of major cell groups in K/BxN and P2rx7−/−.K/BxN mice.
Organ Cell group K/BxN P2rx7−/−.K/BxN
Thymus CD8, CD4 DN (% of TCRβ+) 14.57 ± 1.92 13.10 ± 2.14
CD8, CD4 DP (% of TCRβ+) 76.90 ± 2.86 78.10 ± 3.97
CD8 SP (% of TCRβ+) 1.15 ± 0.15 1.26 ± 0.34
CD4 SP (% of TCRβ+) 1.08 ± 0.16 0.88 ± 0.13
Spleen CD4+ (% of splenocytes) 3.10 ± 0.22 3.47 ± 0.20
CD19+ (% of splenocytes) 73.32 ± 1.15 71.42 ± 1.20
CD11c+ (% of
CD19-TCRβ-Gr-1-)
10.14 ± 1.69 10.08 ± 1.62
CD11b+ (% of
CD19-TCRβ-Gr-1-)
28.05 ± 2.25 30.59 ± 4.22
Gr-1+CD11b+ neutrophils
(% of CD19-TCRβ-)
16.69 ± 0.22 21.82 ± 3.47
PPs CD4+ (% of splenocytes) 3.11 ± 0.32 3.69 ± 0.35
CD19+ (% of splenocytes) 66.48 ± 1.420 59.37 ± 1.861
percentage in the spleen (2.53) is less compared to the PPs
(16.37). This indicates that PP Tfh cells are more sensitive to
P2RX7-mediated apoptosis than splenic Tfh cells. To determine
whether the increase in PP Tfh cells is a Tfh-specific effect, we
also examined PD-1lo/−CXCR5lo/− CD4+ T cells, a population
referred to as “non-Tfh cells,” (29, 41). Our data demonstrated
that there is no change in number or frequency of the non-
Tfh PP population (Supplementary Figure 2A). While there is a
decrease in apoptosis in the P2RX7 deficient non-Tfh population,
it is again less than the decrease in apoptosis of the Tfh population
(Supplementary Figure 2A vs. Figure 2B). We hypothesized
that different expression levels of P2RX7 might explain the
differences in Tfh cell induction and Tfh cell death we detected in
the spleen compared to the PPs. Indeed, while P2RX7 expression
on Tfh cells from both organs exceeded P2RX7 expression on
non-Tfh cells, P2RX7 expression was much higher (>2-fold)
on PP Tfh cells than splenic Tfh cells (Figure 2C). Differential
expression of Bcl-6 could also potentially help explain the
increased Tfh population in P2rx7−/−.K/BxN compared to WT
K/BxN mice. Expression of the transcription factor Bcl-6 in
CD4+ T cells is both necessary and sufficient to drive CD4+ T
cell differentiation into Tfh cells, and thus Bcl-6 is considered
a master regulator of Tfh differentiation (47–49). However,
when we examined Bcl-6 expression in splenic and PP non-
Tfh cells, we found no difference in expression levels between
P2rx7−/− and WT K/BxN mice (Figure 2D). Taken together,
these data suggested that P2RX7 controls the Tfh cell population
by inducing cell death, however lower P2RX7 expression levels
on splenic Tfh cells limit the ability of P2RX7 to control the Tfh
cell population in this systemic site.
T Cell-Intrinsic P2RX7 Deficiency
Enhances Arthritis Development and
Increases the PP Tfh Cell Response
To dissect whether the enhanced Tfh cell response and arthritis
severity observed in P2RX7 deficiency of the whole K/BxN
mouse is mediated by a T cell-intrinsic effect of P2RX7, we
used the K/BxN T cell transfer system (Figure 3A). In this
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FIGURE 2 | P2RX7 deletion induces the Tfh cell response in PPs but not spleen of the SFB(–) K/BxN mice. (A) Splenocytes and PP cells from 5 to 6 week old K/BxN
and P2rx7−/−.K/BxN mice were stained with Abs against CD4, CD19, PD-1, and CXCR5. Values in the representative plots indicate the percentage of Tfh cells in
total CD4+ T cells. Compiled graphs of the number of Tfh cells are also shown as mean + SEM. N = 17–18/group, 8 independent assays combined. (B) Tfh cells
from spleen and PPs of K/BxN and P2rx7−/−.K/BxN mice were analyzed for Annexin V binding among Live/Dead Yellow− cells. Representative plots and compiled
graphs are shown. Ratios calculated by dividing the average of the K/BxN (WT) group by the average of the P2rx7−/−.K/BxN (KO) group. N = 6–7/group, 4
independent assays combined. (C) P2RX7 expression was detected by flow cytometry on non-Tfh and Tfh cells from spleen and PPs of K/BxN and P2rx7−/−.K/BxN
mice. Representative plots and compiled graphs are shown. N = 8–9/group, 3 independent assays combined. (D) Bcl-6 expression was detected by flow cytometry
on non-Tfh cells from spleen and PPs of K/BxN and P2rx7−/−.K/BxN mice. Representative plots and compiled graphs are shown. N = 13–17/group, 6 independent
assays combined. Error bars represent means + SEM. *p < 0.05, **p < 0.01, ****p < 0.0001.
system, arthritis is generated by transferring K/BxN T cells
into TCRα−/−.BxN (T cell deficient B6xNOD) mice, which
allows the transferred K/BxN T cells to recognize GPI peptide
presented on MHC II I-Ag7 and develop arthritis (30, 50).
P2rx7−/− or WT K/BxN CD4+ T cells were transferred into
TCRα−/−.BxN mice as described previously (29). We found
that mice that received P2rx7−/−.K/BxN T cells developed
worse arthritis and had increased anti-GPI auto-Abs, indicating
amplified autoimmunity compared to mice that received WT
K/BxN T cells (Figures 3B,C). Additionally, we found that mice
receiving P2rx7−/−.K/BxN T cells demonstrated a trend toward
an increase in splenic Tfh cells, and a significant increase in
PP Tfh cells compared to mice receiving WT K/BxN T cells
(Figure 3D). We found no change in non-Tfh cells in PPs
between mice that received WT K/BxN or P2rx7−/−.K/BxN T
cells (Figure 3D, Supplementary Figure 2B). Thus, as in total
P2RX7 deletion, our data suggested that T cell-intrinsic P2RX7
deficiency significantly enhanced the Tfh response in the PPs.
However, unlike the total P2RX7 deletion, there was a trend
toward an increase in splenic Tfh cells in the spleen. Consistent
with our data from the whole-mouse P2RX7 knockout system,
we also found that Tfh cell apoptosis was significantly inhibited
in both the spleen and PPs in mice that received P2rx7−/− T
cells compared to those that received WT T cells (Figure 3E).
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FIGURE 3 | P2rx7−/− T cells enhance autoimmunity in the SFB(–) K/BxN T cell transfer model. (A–E) CD4+ T cells were isolated from either WT K/BxN or
P2rx7−/−.K/BxN donors and transferred to TCRα−/−.BxN recipients. (A) Schematic for T cell transfer. (B) Arthritis development was followed by ankle
measurements starting at the day of transfer (day 0). Values are shown as averages of the change in ankle thickness for each individual compared to its first
measurement. N = 20–24/group, 5 assays combined. (C) Auto-Ab titer as determined by ELISA against GPI. N = 20–24/group, 5 assays combined. (D)
Representative plots and compiled graphs of Tfh and non-Tfh cell numbers in spleen and PPs. N = 15–18/group, 4 assays combined. (E) Representative plots of Tfh
and non-Tfh cells stained for Annexin V and Live/Dead Yellow and compiled graphs of Live/Dead Yellow− Annexin V+ Tfh or non-Tfh cells as a percentage of total Tfh
or non-Tfh cells in spleen and PPs. WT = K/BxN, KO = P2rx7−/−.K/BxN. Ratios determined by dividing the average of the WT group by the average of KO group.
N = 8–11/group, 3 assays combined. *p < 0.05 **p < 0.01 ****p < 0.0001.
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FIGURE 4 | Treg numbers do not differ between SFB(–) K/BxN and
P2rx7−/−.K/BxN mice. (A) Representative plots and compiled graphs of Treg
numbers in spleen and PPs of K/BxN and P2rx7−/−.K/BxN mice.
N = 5–11/group, 3 assays combined. (B) P2RX7 surface expression was
detected by flow cytometry on non-Tfh, Tfh, and Treg populations from spleen
and PPs of K/BxN mice. N = 7/group. Error bars represent SEM. ***p < 0.001
****p < 0.0001.
Also, similar to the whole-mouse knockout, the difference in
average percentage of apoptotic splenic Tfh cells between WT
and P2RX7-deficient mice (ratio of WT to KO = 6.85) is less
compared to that of PP Tfh cells (ratio of WT to KO = 11.00).
Interestingly though, the gap between the ratios of spleen and
PP in the T cell transfer model (6.85 and 11.0, Figure 3E) was
less when compared to the whole mouse model (2.53 and 16.37,
Figure 2B). Additionally, we found that WT non-Tfh cells do
not undergo cell death to the same extent as do WT Tfh cells
(Figure 3E). Furthermore, the difference in apoptosis between
WT and P2rx7−/− non-Tfh cells was much less (the average ratio
of WT to P2rx7−/− apoptotic non-Tfh cell frequency was 1.51 in
the spleen and 3.90 for PPs) compared to Tfh cells in both spleen
and PPs (Figure 3E). These results suggested that Tfh cells are
more sensitive to P2RX7-mediated apoptosis than non-Tfh cells,
with the largest apoptotic difference between WT and P2rx7−/−
group occurring in PP Tfh cells.
P2RX7 is also associated with increased cell death in T
regulatory cells (Tregs) in WT B6 mice (51, 52). To verify that
changes in Treg numbers were not responsible for the increased
autoimmunity we observed in the P2rx7−/−.K/BxN mice, we
examined the Treg population in the K/BxN model. We found
that there was no significant change in Treg cell numbers in
P2rx7−/−.K/BxN compared toWTK/BxNmice (Figure 4A).We
also examined P2RX7 protein levels in splenic and PP Tregs by
flow cytometry with non-Tfh and Tfh cells as control groups. We
confirmed that Tfh cells hadmuch higher P2RX7 levels than non-
Tfh cells, as in Figure 2C. Splenic Tregs expressed low P2RX7 at
levels comparable to the non-Tfh cells (Figure 4B). Importantly,
while PP Tregs expressed P2RX7 at higher levels, it was still
lower than P2RX7 expression on splenic Tfh cells, which as a
population, display no difference in cell numbers between WT
and P2rx7−/−.K/BxN mice. This may explain why, analogous
to the splenic Tfh cells, there was also no difference in PP Treg
numbers between WT and P2rx7−/−.K/BxN mice (Figure 4B).
This is supported by the results of another group, who found
that P2RX7 mRNA, while expressed in Tregs, has the highest
expression in Tfh cells (26). We additionally found that there
was no significant change in Treg numbers in the K/BxN transfer
model in mice that received P2rx7−/− T cells compared to those
that received WT T cells (Supplementary Figure 3). Based on
these results, we concluded that Treg depletion is not a driving
force in the increased autoimmunity in P2RX7 deficiency.
SFB Do Not Further Exacerbate
Autoimmune Arthritis in P2rx7−/− Mice
Because Tfh cells have been shown to affect the gut microbiota
and vice versa (26, 29), we examined whether a disease enhancing
gut microbiota might combine with loss of P2RX7 to induce even
greater arthritis development. To address this question, we used
the gut commensal SFB, which we have previously demonstrated
to exacerbate arthritis in the K/BxN system (29, 36). When we
colonized K/BxN and P2rx7−/−.K/BxN mice with SFB [SFB(+)
hereafter], we found that while P2rx7−/− mice trended toward
faster arthritis development than WT mice, the WT mice rapidly
achieved the same level of arthritis (Figure 5A). When we
analyzed anti-GPI auto-Ab titers at the experiment endpoint
(∼age 6 weeks old), we found no difference between SFB(+)
WT and P2rx7−/− mice (Figure 5B). We hypothesized that one
explanation for the lack of difference between WT and P2rx7−/−
mice in the SFB(+) condition could be that, as demonstrated by
another group, P2RX7 actively regulates IgA levels by controlling
the Tfh population, permitting symbiosis with commensal gut
microbes, and in P2rx7−/− mice, SFB levels decrease due to
unregulated IgA production (26). Indeed, when we performed
our standard SFB level analysis 10 days after SFB gavage
(∼age 32 days old) by quantitative PCR in P2rx7−/−.K/BxN
compared to WT K/BxN mice, we found a decrease in SFB
(Figure 5C). However, the decreased SFB colonization levels in
P2rx7−/−.K/BxNmice were still high enough to induce enhanced
autoimmunity in our model based on previous results (29).
To further address the interactions of SFB and P2RX7, we
used T cell-specific P2RX7 deletion and asked how the gut
microbiota might affect the PP Tfh response. P2rx7−/− or WT
K/BxN T cells were transferred into TCRα−/−.BxN mice pre-
colonized with SFB (see Figure 3A). Unlike in mice that were not
colonized with SFB [SFB(–) hereafter], SFB(+) TCRα−/−.BxN
mice that received P2rx7−/− T cells displayed no change in
arthritis development or auto-Ab titer (Figures 5D,E compare
Figures 3B,C). These data demonstrated, similarly to what we
had observed in the complete knockout model, that P2RX7
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FIGURE 5 | SFB colonization negates the difference in disease severity between WT and P2rx7−/− mice in the original K/BxN model and K/BxN T cell transfer
model. (A–G) K/BxN mice (A–C) or TCRα−/−. BxN mice (D–G) were gavaged with SFB 1–2 days after weaning. (A) Ankle thickness was followed over time for
K/BxN and P2rx7−/−.K/BxN mice between ∼3.5 and 6 weeks of age. Data are shown as change in ankle thickness compared to first measurement. Error bars
represent SEM. N = 7–17/group, multiple litters combined. (B) Anti-GPI auto-Ab titers in serum obtained from mice 5–7 weeks old were measured by ELISA.
N = 8–11/group, 5 assays combined. (C) SFB level 10 days after gavage was determined by quantitative PCR on 16S rDNA, normalized to a standardized positive
control. N = 5–12/group, 5 assays combined. (D–G) SFB(+) TCRα−/−.BxN recipients were given either K/BxN or P2rx7−/−.K/BxN CD4+ cells retro-orbitally at 6
weeks of age. (D) Ankle thickness was followed beginning at day of transfer for TCRα−/−.BxN mice transferred with either K/BxN or P2rx7−/−.K/BxN CD4+ cells.
Data are shown as change in ankle thickness compared to first measurement. Error bars represent SEM. N = 12/group, 3 assays combined. (E) Anti-GPI auto-Ab
titers in serum obtained from the end point of each experiment were measured by ELISA. N = 12/group, 3 assays combined. (F) SFB level determined by quantitative
PCR on 16S rDNA, normalized to a standardized positive control. Feces were collected at end point of each experiment (14 days after T cell transfer which was
equivalent to 5 weeks after SFB gavage). N = 23–24/group, 5 assays combined. (G) Representative plots and compiled graphs of spleen and PP Tfh numbers.
N = 11/group, 3 assays combined. **p < 0.01.
deficiency had no additive effect on disease when combined
with SFB colonization. Additionally, we found that unlike in
P2RX7 deficiency in the whole organism, in our T cell transfer
model, T cell-specific P2RX7 deficiency did not change the SFB
level after transfer (Figure 5F). As this study was done in the
transfer model, to measure the transferred T cells effects on
SFB colonization, we analyzed SFB level at a much later stage
(two weeks after transfer which was equivalent to 5 weeks after
SFB gavage) compared to the whole mouse deletion (measured
10 days after SFB gavage, Figure 5C), and thus their SFB
levels had declined from initial levels, as has been noted in
our previous reports (44). Nevertheless, unlike in whole mouse
deletion (Figure 5C), T cell-specific P2RX7 deletion does not
further reduce the SFB level (Figure 5F). This suggests that
P2RX7 deficiency in T cells alone is not enough to inhibit SFB
colonization levels, at least in the K/BxN arthritis model. When
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we further examined Tfh cells in SFB(+) transfer mice, we found
that although there was a slight upward trend in Tfh numbers
in mice that received P2rx7−/− T cells compared to those that
received WT cells, there was no significant difference in either
the spleen or the PPs (Figure 5G).
Up-Regulation of TIGIT Corresponds With
a Reduction in Apoptosis in P2rx7−/− Tfh
Cells
Because we observed enhanced Tfh cell responses and reduced
apoptotic Tfh cells in mice with both complete and T cell-
intrinsic P2RX7 deficiency under SFB(–) conditions, we next
investigated the molecular mechanism whereby P2RX7 exerted
its pro-apoptotic effect in SFB(–) mice. In chronic infections
and cancer, T cells are exposed to persistent antigens, causing
T cell dysfunction, a state called “exhaustion” (53, 54). An
important characteristic of exhausted T cells is that these T
cells do not undergo cell death, but instead become inactive
and unresponsive to stimulation (55). Indeed, activation of
TIGIT, a well-known T cell exhaustion marker, up-regulates
anti-apoptotic molecules and promotes T cell survival (56).
Because of the reduced apoptosis in Tfh cells derived from
P2rx7−/−.K/BxN mice, we asked whether P2RX7 deficiency in
T cells might reduce apoptotic Tfh cells by modulating TIGIT.
To investigate this question, we examined the expression levels
of TIGIT on P2rx7−/− or WT K/BxN T cells transferred into
SFB(–) TCRα−/−.BxNmice (57).We found an increase in TIGIT
expression on both splenic and PP P2rx7−/−.K/BxN Tfh cells
compared to WT K/BxN T cells (Figures 6A,B). To further
determine the role of TIGIT up-regulation in P2RX7-deficient
Tfh cells, we examined cell death between TIGIT+ and TIGIT−
Tfh cells. We found that splenic and PP TIGIT+ Tfh cells, in
both mice that received WT and those that received P2rx7−/−
T cells, were associated with a decrease in apoptosis, as detected
by Annexin V staining among Live/Dead Yellow negative cells,
compared to TIGIT− Tfh cells (Figures 7A,B). In P2rx7−/−
TIGIT− Tfh cells, which were already far less susceptible to cell
death than WT TIGIT− Tfh cells, the expression of TIGIT was
associated with a further reduction in the apoptotic Tfh cell
population both in the spleens and in the PPs.
DISCUSSION
P2RX7 has garnered a lot of interest in recent years as a
potential therapeutic target for autoimmune arthritis and many
other diseases (17, 19, 25). However, the results have been
inconsistent and sometimes contradictory. We aimed to further
elucidate the role of P2RX7 in autoimmunity by using the
spontaneous autoimmune arthritis K/BxN model, along with
adoptive transfers to limit the effects of P2RX7 deficiency
specifically in T cells. We found that P2RX7 deficiency in the
original K/BxN model led to worsened arthritis and higher auto-
Ab titers. In addition, examination of Tfh cells revealed the
differential impact of P2RX7 in systemic and mucosal tissues:
while splenic Tfh cells changed little, PP Tfh cells increased in
the absence of P2RX7, despite the fact that Tfh cells in both
organs experienced a disruption of cell death. We further found
that T cell-intrinsic P2RX7 ablation is sufficient to generate
an autoimmune-exacerbation effect similar to that of P2RX7
deficiency in the whole mouse, i.e., an increase in arthritis, auto-
Ab titers, and PP Tfh cell numbers. Many P2RX7 antagonists
were designed for anti-inflammatory purposes (19). Our finding
that P2RX7 deficiency mediated autoimmune arthritis counters
these anti-inflammatory purposes, as we demonstrated that
P2RX7 deficiency enhances rather than reduces autoimmune
arthritis. We believe the conflicting beneficial or detrimental
effects of P2RX7 inhibition could be based on the various
etiopathogenesis in different diseases. For example, P2RX7
inhibition would likely enhance those autoimmune diseases that
are mediated by auto-Abs and Tfh cells such as is seen here in
the K/BxN model and in EAE models reported previously (21).
In contrast, diseases that are mediated by innate immune players
may be ameliorated by P2RX7 inhibition, which targets the IL-1
and IL-18 pathways (19).
Interestingly, when we colonized mice with SFB in either our
K/BxN or T cell transfer model, we found that SFB colonization
negated the difference observed between WT and P2RX7-
deficient mice. We have previously reported that SFB enhanced
the PP Tfh cell response inWTK/BxNmice and the K/BxN T cell
transfer model, and PP Tfh cells are required for SFB-mediated
arthritis enhancement (29). SFB-mediated disease enhancement
can also be demonstrated when compared arthritis and anti-GPI
titers between SFB (-) and (+) WT K/BxN mice in the current
study (Figures 1A,B vs. Figures 5A,B). Thus, we suspect the lack
of disease difference between SFB (+) WT and P2RX7-deficient
mice is most likely because SFB do not further increase the PP
Tfh cell response in P2RX7 deficient mice (compare Figure 3D
and Figure 5G). We speculate that the lack of arthritis difference
between WT and KO groups in the SFB (+) condition could be
due to an overlapping effect between SFB and P2RX7 deficiency
in enhancing arthritis development.More studies will be required
to determine the exact mechanism of whether and how SFB
may inhibit P2RX7 signaling to enhance Tfh cell responses
and arthritis development. Our data also suggested that gut
microbiota composition may account for some of the disparities
in P2RX7 effects in previous studies. Notably, microbe-host
interactions where the host impacts the microbiota have also
been observed in regard to P2RX7 deficiency. For example,
P2RX7 deficiency has been previously demonstrated to trigger an
enhanced PP Tfh cell response, leading to greater IgA production
by B cells to inhibit SFB colonization (26). This effect likely
requires the combination of T cell-specific and B cell-specific
P2RX7 deficiency, as we found that SFB colonization was reduced
with whole-mouse but not T cell-intrinsic P2RX7 deficiency. Our
T cell transfer data showing no difference in arthritis (Figure 5D)
and SFB level (Figure 5F) between P2RX7-deficient and WT
groups indicate that lower SFB levels in whole-mouse P2RX7
deficiency (Figure 5C) was not solely responsible for the lack of
arthritis difference between WT and P2rx7−/− mice in SFB(+)
condition (Figures 5A,D) when compared to SFB(–) condition
(Figures 1A, 3B). Future studies will be required to understand
the mechanisms involved in microbiota-mediated autoimmunity
in the absence of P2RX7.
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FIGURE 6 | TIGIT is increased on P2rx7−/− Tfh cells in the SFB(–) K/BxN transfer model. (A,B) Representative histograms and compiled graphs of TIGIT expression
on (A) splenic or (B) PP Tfh cells from WT or P2rx7−/−.K/BxN CD4+ cells transferred into TCRα−/−.BxN mice. Compiled graphs show TIGIT+ Tfh as a percentage
of total Tfh cells. N = 7–9/group, 2 assays combined. **p < 0.01 ****p < 0.0001.
FIGURE 7 | TIGIT expression on Tfh cells is associated with decreased apoptosis in the SFB(–) K/BxN transfer model. (A,B)WT or P2rx7−/−.K/BxN CD4+ cells were
transferred into TCRα−/−. BxN recipients. Shown are representative plots and compiled graphs of Live/Dead Yellow− Annexin V+ staining as a percentage of either
TIGIT+ or TIGIT− Tfh cells. N = 11–14/group, 3 assays combined. *p < 0.05 **p < 0.01 ****p < 0.0001.
Notably, we identified a significant increase in TIGIT
expression on P2rx7−/− Tfh cells. As mentioned earlier,
activation of TIGIT up-regulates anti-apoptotic molecules and
promotes T cell survival (56). In P2rx7−/− TIGIT− Tfh cells,
which were already far less susceptible to cell death than WT
TIGIT− Tfh cells, the expression of TIGIT was associated with
a further reduction of the apoptotic Tfh cell population both in
the spleens and in the PPs (Figure 8). These data suggested that
P2RX7 can promote cell death in the Tfh population through
a TIGIT-independent mechanism (Figure 8). Our data further
suggested that P2RX7 could potentially promote cell death in
the Tfh population by down-regulating TIGIT and inhibiting
TIGIT’s anti-apoptotic effect. Clearly, more future studies need to
be done to address the apoptotic regulation by P2RX7 and TIGIT.
TIGIT has historically been viewed as an inhibitory molecule,
which signals via ITIM domains to inhibit T cell activation
(56, 57). However, more recent work has identified TIGIT+ Tfh
cells as drivers of the immune response (58, 59). TIGIT, though
it has been associated with T cell exhaustion, may have other
roles as well. A pathogenic role for TIGIT has been implicated by
two other groups, one of which demonstrated that a pathogenic
subset of Tfh cells circulating in human RA patients’ blood can
be identified in part by enhanced expression of TIGIT (59), and
the other of which demonstrated increased B cell costimulatory
activity in a TIGIT+ subset of Tfh cells, which is inhibited by
anti-TIGIT blocking antibodies (58).
Consistent with previous results from another group (26), we
found an induction of the PP Tfh population and little change
in the splenic Tfh response in P2rx7−/−.K/BxN mice compared
to K/BxN mice. One explanation for the difference between the
mucosal and systemic sites could be the much higher P2RX7
expression in PP compared to splenic Tfh cells (>2-fold), as
detected in the whole-mouse model. This would make PP Tfh
cells more sensitive to P2RX7-induced cell death than splenic Tfh
cells, as the ratio of WT to P2rx7−/−.K/BxN apoptotic Tfh cells
in the spleen compared to the PPs is 2.53 and 16.37, respectively,
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FIGURE 8 | Model of interactions between P2RX7 and TIGIT, and their impact
on cell death. (A) P2RX7 promotes apoptosis in PP Tfh cells to regulate Tfh
numbers. P2RX7 may also regulate TIGIT expression on Tfh cells. TIGIT,
conversely, may inhibit apoptosis to promote Tfh cell survival. (B) In the
absence of P2RX7, apoptosis is disrupted, allowing the expansion of the PP
Tfh population. In addition, the absence of P2RX7 leads to greater TIGIT
expression, which may further down-regulate apoptosis.
indicating greater P2RX7-mediated apoptosis in the PPs than
the spleen. We have further confirmed the PP Tfh induction
phenotype using P2rx7−/−.K/BxN T cells in the transfer model.
Interestingly, T cell-intrinsic P2RX7 deficiency induced the PP
Tfh response and it almost significantly induced the Tfh cell
response in the spleen as well. This corresponded with the
increased ratio of WT to P2rx7−/−.K/BxN apoptotic Tfh cells in
spleen of T cell-specific deletion experiments when compared to
that of whole mouse deletion experiments (2.53). These results
suggested that P2RX7 deficiency in T cells alone allow T cells
to be more sensitive to P2RX7-mediated deletion in systemic
sites. Finally, regardless of the system, there were higher ratios
of WT to P2rx7−/−.K/BxN apoptotic Tfh cells in PPs compared
to the spleen. This may be due to the unique environment of the
PPs, because commensal bacteria can serve as a major source of
intestinal luminal ATP to activate P2RX7 (60, 61).
Similarly to Tfh cells, P2RX7 has generally been associated
with increased cell death in Tregs (51, 52). Thus, the effect
of P2RX7 deficiency on Tregs would likely increase Treg cell
numbers, and would be unlikely to explain the increase in
autoimmunity observed in P2rx7−/−.K/BxN mice. In the K/BxN
autoimmune model, we did not observe a difference in Treg cell
number between WT and P2rx7−/− groups. Thus, it appears
that in WT B6 mice, Tregs are more sensitive to P2RX7-induced
apoptosis than the Tregs under autoimmune conditions. P2RX7
inhibits mTOR, which is a critical regulator of Tfh cells (62, 63).
Activation of mTORC1 and mTORC2 expands Tfh and depletes
regulatory T cells (64). Due to limitations on the scope of this
study, we did not investigate the role of mTOR in P2RX7-
medaited apoptosis. Undoubtedly, more studies will be required
to address this important question.
In conclusion, contrary to the expected anti-inflammatory
effect of P2RX7 inhibition through down-regulating innate
immune responses (19), T cell-specific P2RX7 inhibition
effectively enhanced K/BxN inflammatory arthritis. This effect
was associated with an enhancement of the mucosal (but
not systemic) Tfh cell response. These data suggest that non-
selective P2RX7 antagonists may not be very effective in
ameliorating autoimmune diseases, which may explain the
failures in previous P2RX7-antagonist clinical trials with RA.
Interestingly, a recent report suggests that P2RX7 is required
for the establishment, maintenance and functionality of long-
lived memory CD8+ T cell populations but not short-lived
effector CD8+ T cells (65). These findings suggest that activation
of P2RX7 by extracellular ATP can generate a variety of, or
even opposite, outcomes based on the cell type (66). Our
results illustrate a valuable lesson that cell-specific targeting of
P2RX7 should be considered in order to achieve efficacy for
P2RX7-related therapy.
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